Plain-English translation of NCT07903623 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether , a new type of antibody medication, works better when combined with another antibody called in treating newly diagnosed primary plasma cell leukemia—a rare and serious blood cancer. All participants will receive both medications together to see if this combination helps more patients achieve remission and stay in remission longer. The study will also track any side effects to make sure the treatment is safe.
Primary plasma cell leukemia is a very aggressive blood cancer that is hard to treat, and many patients who receive standard treatments still have disease that comes back. This trial is testing whether this new combination of medications can help more patients respond to treatment and stay cancer-free for longer.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will receive two medications—one as a subcutaneous injection (under the skin) and one as an intravenous infusion (into a vein)—in repeating 28-day cycles for up to 18 cycles (about 1.5 years). You will have regular blood tests and bone marrow exams to check how well the treatment is working and monitor for side effects. After the first 3 cycles, you may also undergo a procedure to collect your own blood stem cells, which could be used for a future transplant if needed.
AI-generated summary from trial data · Nov 17, 2026 · Not medical advice
China